SRR6013566
— · cohortMD2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD2
- subtype
- cohortMD2
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UV_RESPONSE_DN+0.380
- INTERFERON_ALPHA_RESPONSE+0.360
- INTERFERON_GAMMA_RESPONSE+0.320
- PROTEIN_SECRETION+0.320
- ALLOGRAFT_REJECTION+0.310
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.310
- KRAS_SIGNALING_UP+0.280
- COMPLEMENT+0.250
- INFLAMMATORY_RESPONSE+0.170
- ANDROGEN_RESPONSE+0.150
Top 10 suppressed
- MYC_TARGETS_V2-0.530
- GLYCOLYSIS-0.380
- E2F_TARGETS-0.300
- ESTROGEN_RESPONSE_LATE-0.290
- P53_PATHWAY-0.290
- WNT_BETA_CATENIN_SIGNALING-0.280
- CHOLESTEROL_HOMEOSTASIS-0.260
- G2M_CHECKPOINT-0.260
- MTORC1_SIGNALING-0.250
- MYC_TARGETS_V1-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518405 | — | A | 0.858 |
| 2 | TCGA-55-7816-01A-11R-2170-07 | — | cohortMD2 | 0.833 |
| 3 | TCGA-99-7458-01A-11R-2039-07 | — | cohortA1 | 0.821 |
| 4 | 2b1fa47d-360a-4b4a-aa11-23bdb025b559 | — | — | 0.810 |
| 5 | TCGA-BH-A1EU-01A-11R-A137-07 | — | A | 0.803 |
| 6 | SRR8518195 | — | A | 0.799 |
| 7 | TCGA-44-A479-01A-31R-A24H-07 | — | cohortA3 | 0.791 |
| 8 | C3L-02957 | — | cohortMD2 | 0.787 |
| 9 | TCGA-44-2665-01A-01R-A278-07 | — | cohortMD2 | 0.786 |
| 10 | TCGA-E9-A24A-01A-11R-A169-07 | — | B | 0.786 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UV_RESPONSE_DN | 0.380 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.360 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.320 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.320 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.310 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.310 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.280 | Inavolisib | — uncovered |
| COMPLEMENT | 0.250 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.170 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.150 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.140 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.130 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.120 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.120 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.120 | Idelalisib | — uncovered |
| COAGULATION | 0.090 | Binimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.080 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.070 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.050 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.010 | Remibrutinib | — uncovered |